Laboratorio di Ematologia Oncologica, Centro di Ricerca in Medicina Sperimentale (CeRMS), and Divisione Universitaria di Ematologia, Ospedale San Giovanni Battista di Torino e Universita' degli Studi di Torino, Turin, Italy.
Cell Mol Life Sci. 2011 Jul;68(14):2419-32. doi: 10.1007/s00018-011-0704-8. Epub 2011 May 17.
Many hematological malignancies consist of tumor cells that are spontaneously recognized and killed by Vγ9Vδ2 T cells. These tumor cells generate high amounts of intracellular phosphorylated metabolites mimicking the natural ligands and display a wide range of stress-induced self-ligands that are recognized by Vγ9Vδ2 T cells via TCR-dependent and TCR-independent mechanisms. The intrinsic features of Vγ9Vδ2 T cells and that of tumor cells of hematological origin constitute an ideal combination from which to develop Vγ9Vδ2 T cell-based immune interventions. In this review, we will discuss the rationale, preclinical and clinical data in favor of this therapeutic strategy and the future perspectives of its development.
许多血液恶性肿瘤由肿瘤细胞组成，这些肿瘤细胞被 Vγ9Vδ2 T 细胞自发识别和杀伤。这些肿瘤细胞产生大量模拟天然配体的细胞内磷酸化代谢物，并显示出广泛的应激诱导的自身配体，这些配体通过 TCR 依赖和 TCR 非依赖机制被 Vγ9Vδ2 T 细胞识别。Vγ9Vδ2 T 细胞的固有特征和血液来源的肿瘤细胞的固有特征构成了开发基于 Vγ9Vδ2 T 细胞的免疫干预的理想组合。在这篇综述中，我们将讨论支持这种治疗策略的原理、临床前和临床数据以及其发展的未来前景。
